BIOSINO BIO-TEC (08247) announced that the company recently received a notice from Beijing Saipu Asset Management Co., Ltd. (Beijing Saipu). Beijing Saipu signed an "Equity Transaction Contract" with Shandong Boke BIOSINO Technology Co., Ltd. (Boke BIOSINO) on December 18, 2025, agreeing to legally transfer its 31.3086 million domestic shares in the company (approximately 21.64% of the total issued shares) to Boke BIOSINO. The transfer has completed the relevant procedures at the Beijing Equity Exchange. On December 31, 2025, both parties completed the share transfer and ownership change formalities with the relevant share registration authority. Effective immediately, Boke BIOSINO has officially become a shareholder holding approximately 21.64% of the company's shares. Boke BIOSINO is a technology-based enterprise established in Shandong Province, China, primarily engaged in medical device equipment, biopharmaceutical technology, medical informatization, and integrated laboratory solutions, operating as a comprehensive enterprise integrating R&D, production, sales, and service. According to public information, Boke BIOSINO is indirectly wholly owned by Gan Yiwen and Chu Danxia. Following the completion of this transfer, Beijing Saipu no longer holds any shareholding interests in the company and ceases to be a major shareholder; Boke BIOSINO now holds 31.3086 million domestic shares of the company (approximately 21.64% of the total issued shares) and has become a major shareholder.